BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3097666)

  • 1. The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience).
    Franssen AM; Kauer FM; Rolland R; Zijlstra JA; Willemsen WN; van 't Veen AJ
    Prog Clin Biol Res; 1986; 225():201-10. PubMed ID: 3097666
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience).
    Cirkel U; Schweppe KW; Ochs H; Schneider HP
    Prog Clin Biol Res; 1986; 225():189-99. PubMed ID: 3097665
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.
    Minaguchi H; Uemura T; Shirasu K
    Prog Clin Biol Res; 1986; 225():211-25. PubMed ID: 3097667
    [No Abstract]   [Full Text] [Related]  

  • 4. A preliminary report on the comparative use of buserelin (Hoe 766) and danazol in the treatment of endometriosis: the University of Southern California experience.
    Yee B
    Prog Clin Biol Res; 1986; 225():175-88. PubMed ID: 3097664
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
    Lemay A; Maheux R; Jean C; Faure N
    Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
    Shaw RW; Matta W
    Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R; Lemay A
    Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
    Raitz von Frentz M; Schweppe KW
    Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
    Negri P; Ricciardelli MA; Tomasi A; Grechi E; Fortini RM
    Acta Eur Fertil; 1992; 23(4):171-4. PubMed ID: 1343472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
    Schindler AE; Bühler K; Mettler L; Fuchs U; Cirkel U; Ochs H; Schweppe KW; Koch R
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
    Rolland R; Franssen AM; Willemsen WN; Corbey RS
    Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of LHRH agonist therapy in the treatment of endometriosis (English experience).
    Jelley RY; Magill PJ
    Prog Clin Biol Res; 1986; 225():227-38. PubMed ID: 3097668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonal changes in buserelin therapy].
    Fuchs U; Zwirner M
    Zentralbl Gynakol; 1989; 111(18):1236-40. PubMed ID: 2511705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial results in the treatment of endometriosis with the LH-RH analog buserelin].
    Hardt W; Schmidt-Gollwitzer M; Schmidt-Gollwitzer K; Genz T; Nevinny-Stickel J
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):483-9. PubMed ID: 3093311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients.
    Franssen AM; Rolland R; Chadha DR; Willemsen WN; Vemer HM
    Eur J Obstet Gynecol Reprod Biol; 1986 Dec; 23(5-6):379-86. PubMed ID: 3100357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LHRH agonist and contraception.
    Hoffmann G; Schommer M; Pollow K; von der Ohe M
    Prog Clin Biol Res; 1986; 225():325-35. PubMed ID: 3097671
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin).
    Sirimongkolkasem R; Rojanasakul A; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():37-41. PubMed ID: 2112582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserelin spray and buserelin implant, in the treatment of endometriosis associated infertility.
    Donnez J; Nisolle M; Clerckx F; Casanas F
    Prog Clin Biol Res; 1990; 323():427-42. PubMed ID: 2106147
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of endometriosis with domestic luteinizing hormone--releasing hormone analogue].
    Geng L; Gu FY; Zhang LZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):592-4, 636. PubMed ID: 7712871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.